SCHEMBL22390530

SCHEMBL22390530

CC(C)(C)Cc1ccccc1OCC1CCCC1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 2/20 0.88
▸ HTR2C P28335 3/20 0.45
▸ MCHR1 Q99705 3/20 0.43
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ FAAH O00519 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22391548 0.97 RIPK1 (0.88) RIPK1HTR2CMCHR1SLC6A2SLC6A4
SCHEMBL22391510 0.94 RIPK1 (1.00) RIPK1HTR2CSLC6A2SLC6A4SLC6A3
SCHEMBL22390621 0.84 RIPK1 (0.76) RIPK1HTR2CSLC6A2SLC6A4SLC6A3
SCHEMBL22391953 0.82 RIPK1 (0.61) RIPK1HTR2CMCHR1SLC6A2SLC6A4
SCHEMBL22957672 0.82 RIPK1 (0.60) RIPK1HTR2CMCHR1SLC6A2SLC6A4
SCHEMBL7318282 0.81 RIPK1 (0.58) RIPK1HTR2CMCHR1BRD4FAAH
SCHEMBL22957816 0.79 RIPK1 (0.60) RIPK1HTR2CMCHR1SLC6A2SLC6A4
SCHEMBL29786424 0.79 RIPK1 (0.55) RIPK1HTR2CMCHR1SLC6A2SLC6A4
SCHEMBL20472415 0.79 RIPK1 (0.55) RIPK1HTR2CMCHR1SLC6A2SLC6A4
SCHEMBL24180094 0.78 RIPK1 (0.55) RIPK1HTR2CMCHR1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200277296-A1 AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200277296-A1 AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS RIPK1, RIPK4, RIPK3 RIPK1 1/4885HTR2C 3194/4885MCHR1 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback